HAVN Life Sciences Income Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020
Period Ending	Jan '23 Jan 31, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021	Apr '20 Apr 30, 2020
Revenue	0.59	0.28	-	-
Cost of Revenue	0.38	0.19	-	-
Gross Profit	0.21	0.09	-	-
Selling, General & Admin	2.61	4.94	4.92	0.49
Research & Development	0.5	0.66	0.33	-
Operating Expenses	3.8	8.07	19.43	0.49
Operating Income	-3.6	-7.98	-19.43	-0.49
Interest Expense	-0.02	-0.06	-0.02	-
Interest & Investment Income	0.03	0.03	-	0.01
Currency Exchange Gain (Loss)	-0.01	-0.03	-0.01	-
Other Non Operating Income (Expenses)	-1.51	-2.61	-10.93	-
EBT Excluding Unusual Items	-5.1	-10.65	-30.38	-0.49
Asset Writedown	-9.84	-11.79	-	-
Pretax Income	-15.71	-22.44	-30.38	-0.49
Net Income	-15.71	-22.44	-30.38	-0.49
Net Income to Common	-15.71	-22.44	-30.38	-0.49
Shares Outstanding (Basic)	7	4	2	0
Shares Outstanding (Diluted)	7	4	2	0
Shares Change (YoY)	84.53%	118.42%	1782.66%	-
EPS (Basic)	-2.20	-5.25	-15.51	-4.68
EPS (Diluted)	-2.20	-5.25	-15.51	-4.68
Free Cash Flow	-2.61	-7.98	-10.45	-0.9
Free Cash Flow Per Share	-0.37	-1.86	-5.34	-8.65
Gross Margin	35.54%	32.44%	-	-
Operating Margin	-612.60%	-2885.50%	-	-
Profit Margin	-2676.59%	-8117.81%	-	-
Free Cash Flow Margin	-444.52%	-2885.68%	-	-
EBITDA	-3.5	-7.5	-14.85	-
D&A For EBITDA	0.09	0.48	4.58	-
EBIT	-3.6	-7.98	-19.43	-0.49
Advertising Expenses	-	0.21	0.33	-

Updated Apr 4, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.